董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Wilfred E. Jaeger | 男 | Director | 62 | 14.09万美元 | 未持股 | 2018-02-26 |
| Thomas G. Auchincloss, Jr. | 男 | Director | 56 | 14.34万美元 | 未持股 | 2018-02-26 |
| Wendell Wierenga | 男 | Director | 70 | 未披露 | 未持股 | 2018-02-26 |
| Meghan FitzGerald | 女 | Director | 47 | 13.34万美元 | 未持股 | 2018-02-26 |
| Wendell Wierenga | 男 | Director | 70 | 13.14万美元 | 未持股 | 2018-02-26 |
| Peter Barton Hutt | 男 | Director | 83 | 12.07万美元 | 未持股 | 2018-02-26 |
| Christine van Heek | 女 | Director | 61 | 13.59万美元 | 未持股 | 2018-02-26 |
| Roger D. Tung | 男 | Director, Chief Executive Officer and President | 58 | 343.09万美元 | 未持股 | 2018-02-26 |
| Richard H. Aldrich | 男 | Director and Chairman of the Board | 63 | 16.77万美元 | 未持股 | 2018-02-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lynette A. Herscha | 女 | General Counsel | 46 | 未披露 | 未持股 | 2018-02-26 |
| James V. Cassella | 男 | Chief Development Officer | 63 | 196.02万美元 | 未持股 | 2018-02-26 |
| Roger D. Tung | 男 | Director, Chief Executive Officer and President | 58 | 343.09万美元 | 未持股 | 2018-02-26 |
| Nancy Stuart | 女 | Chief Operating Officer | 59 | 194.73万美元 | 未持股 | 2018-02-26 |
| Marc Becker | 男 | Chief Financial Officer | 46 | 未披露 | 未持股 | 2018-02-26 |
董事简历
中英对照 | 中文 | 英文- Wilfred E. Jaeger
-
Wilfred E. Jaeger，2012年1月起，担任本公司董事。1993年，他参与创办Three Arch Partners，并担任合伙人、管理成员。共同创办Three Arch Partners之前，他是Schroder Ventures的普通合伙人。他目前担任Concert Pharmaceuticals（临床阶段上市制药公司）、Threshold Pharmaceuticals（上市制药公司），以及许多私营公司的董事。他在University of British Columbia获得生物学士学位，在University of British Columbia School of Medicine获得医学博士学位，在Stanford Graduate School of Business获得工商管理硕士学位。
Wilfred E. Jaeger has served on our board of directors since January 2012. Dr. Jaeger cofounded Three Arch Partners in 1993 and has served as a Partner and Managing Member since that time. Prior to co-founding Three Arch Partners, Dr. Jaeger was a general partner at Schroder Ventures. Dr. Jaeger currently serves on the board of directors of Concert Pharmaceuticals, Inc., a public clinical stage biopharmaceutical company, as well as numerous private companies. Dr. Jaeger received a B.S. in Biology from the University of British Columbia, an M.D. from the University of British Columbia School of Medicine and an M.B.A from the Stanford Graduate School of Business. - Wilfred E. Jaeger，2012年1月起，担任本公司董事。1993年，他参与创办Three Arch Partners，并担任合伙人、管理成员。共同创办Three Arch Partners之前，他是Schroder Ventures的普通合伙人。他目前担任Concert Pharmaceuticals（临床阶段上市制药公司）、Threshold Pharmaceuticals（上市制药公司），以及许多私营公司的董事。他在University of British Columbia获得生物学士学位，在University of British Columbia School of Medicine获得医学博士学位，在Stanford Graduate School of Business获得工商管理硕士学位。
- Wilfred E. Jaeger has served on our board of directors since January 2012. Dr. Jaeger cofounded Three Arch Partners in 1993 and has served as a Partner and Managing Member since that time. Prior to co-founding Three Arch Partners, Dr. Jaeger was a general partner at Schroder Ventures. Dr. Jaeger currently serves on the board of directors of Concert Pharmaceuticals, Inc., a public clinical stage biopharmaceutical company, as well as numerous private companies. Dr. Jaeger received a B.S. in Biology from the University of British Columbia, an M.D. from the University of British Columbia School of Medicine and an M.B.A from the Stanford Graduate School of Business.
- Thomas G. Auchincloss, Jr.
-
Thomas G. Auchincloss, Jr.自2014年12月起担任公司董事会的成员。在2013年10月他担任Counterpoint Trading Company有限责任公司（Counterpoint Trading Company, LLC，一家私人投资公司）的管理合伙人。2005年5月-2007年8月他在Metabolix股份有限公司（Metabolix, Inc，公共生物材料公司）担任财务总监。在加入Metabolix之前（2002年4月-2005年5月）他担任Metabolix的顾问，提供商业拓展，财务和战略咨询服务。1994-2001年他在Vertex Pharmaceuticals Incorporated担任许多职位，目前担任财务副总裁和财务主管。他是Kieve Wavus Education股份有限公司（Kieve Wavus Education, Inc，一个非盈利的营地和教育组织）的受托人和财务主管。他也担任Capital Formation Group股份有限公司（Capital Formation Group Inc，一家家庭投资公司）和Acelium（网络安全公司）的咨询师。他拥有巴布森学院（Babson College）商业管理学士学位和沃顿商学院（Wharton School）关于财务的工商管理硕士学位。
Thomas G. Auchincloss, Jr. has served as a member of our Board of Directors since December 2014. Since October 2013 Mr. Auchincloss has served as Managing Partner at Counterpoint Trading Company, LLC, a private investment firm. From August 2007 through September 2013 Mr. Auchincloss was self-employed in private investing. From May 2005 to August 2007 Mr. Auchincloss worked as Chief Financial Officer of Metabolix, Inc., a public biomaterials company. Prior to joining Metabolix, Mr. Auchincloss served as a consultant with Metabolix, from April 2002 to May 2005 providing business development, financial and strategic consulting services. From 1994 to 2001 Mr. Auchincloss served in a variety of positions at Vertex Pharmaceuticals Incorporated, most recently as Vice President, Finance and Treasurer. Mr. Auchincloss received a B.S. in Business Administration from Babson College and an M.B.A. in Finance from the Wharton School. - Thomas G. Auchincloss, Jr.自2014年12月起担任公司董事会的成员。在2013年10月他担任Counterpoint Trading Company有限责任公司（Counterpoint Trading Company, LLC，一家私人投资公司）的管理合伙人。2005年5月-2007年8月他在Metabolix股份有限公司（Metabolix, Inc，公共生物材料公司）担任财务总监。在加入Metabolix之前（2002年4月-2005年5月）他担任Metabolix的顾问，提供商业拓展，财务和战略咨询服务。1994-2001年他在Vertex Pharmaceuticals Incorporated担任许多职位，目前担任财务副总裁和财务主管。他是Kieve Wavus Education股份有限公司（Kieve Wavus Education, Inc，一个非盈利的营地和教育组织）的受托人和财务主管。他也担任Capital Formation Group股份有限公司（Capital Formation Group Inc，一家家庭投资公司）和Acelium（网络安全公司）的咨询师。他拥有巴布森学院（Babson College）商业管理学士学位和沃顿商学院（Wharton School）关于财务的工商管理硕士学位。
- Thomas G. Auchincloss, Jr. has served as a member of our Board of Directors since December 2014. Since October 2013 Mr. Auchincloss has served as Managing Partner at Counterpoint Trading Company, LLC, a private investment firm. From August 2007 through September 2013 Mr. Auchincloss was self-employed in private investing. From May 2005 to August 2007 Mr. Auchincloss worked as Chief Financial Officer of Metabolix, Inc., a public biomaterials company. Prior to joining Metabolix, Mr. Auchincloss served as a consultant with Metabolix, from April 2002 to May 2005 providing business development, financial and strategic consulting services. From 1994 to 2001 Mr. Auchincloss served in a variety of positions at Vertex Pharmaceuticals Incorporated, most recently as Vice President, Finance and Treasurer. Mr. Auchincloss received a B.S. in Business Administration from Babson College and an M.B.A. in Finance from the Wharton School.
- Wendell Wierenga
-
Wendell Wierenga，2014年9月以来，他一直担任我们董事会的成员。他是一个经验丰富的制药执行官，拥有研究、药物发现和药物开发各方面的丰富经验。从2011年6月到2014年2月，他担任Santarus公司（公共生物制药公司，于2014年1月被Salix Pharmaceuticals公司收购）的研发执行副总裁。从2007年到2011年5月，他曾担任Ambit Biosciences Corporation的执行副总裁，负责研发。从2003年到2007年，他曾担任Neurocrine Biosciences公司的负责研发的执行副总裁。从2000年到2003年，他曾担任Syrrx公司的首席执行官。从1990年到2000年，他曾担任Parke-Davis公司（Warner Lambert公司的一个部门）的全球制药科学、技术和发展的副总裁。任职Parke-Davis公司之前，他曾任职Upjohn Co。及其继任公司16年，担任多种职务，最近担任负责发现研究的执行董事。此外，他是XenoPort公司、Cytokinetics公司、Ocera Therapeutics公司、Apricus Biosciences公司、Concert Pharmaceuticals公司的董事。在之前的五年里，他此前也曾任职于Onyx Pharmaceuticals公司的董事会。他持有Hope College的学士学位，以及Stanford University的化学博士学位。
Wendell Wierenga has served as a member of our Board of Directors since February 2011. From June 2011 to January 2014 Dr. Wierenga served as Executive Vice President, Research and Development, at Santarus, Inc., acquired by Salix Inc., which was subsequently acquired by Valeant Pharmaceuticals International, Inc. From 2006 to 2011 he served as Executive Vice President, Research and Development, at Ambit Biosciences Corporation. From 2003 to 2006 he served as Executive Vice President of Research and Development at Neurocrine Biosciences, Inc. From 2000 to 2003 Dr. Wierenga served as Chief Executive Officer of Syrrx, Inc. now part of Takeda Pharmaceutical Company. From 1990 to 2000 he was Senior Vice President of Worldwide Pharmaceutical Sciences, Technologies and Development at Parke-Davis/Warner Lambert (now Pfizer, Inc.). Prior to that, Dr. Wierenga spent 16 years at Upjohn Pharmaceuticals in research and drug discovery roles, most recently as Executive Director of Discovery Research. Dr. Wierenga has served on the Board of Directors of Crinetics Pharmaceuticals since 2014 and Dermata Therapeutics since September 2016. He also served on the Board of Directors of Onyx Pharmaceuticals, Inc. from 1996 to 2013 XenoPort, Inc. from 2001 to August 2016 Ocera Therapeutics, Inc. from December 2013 to December 2018 Anacor Pharmaceuticals, Inc. from September 2014 to July 2016 Apricus Biosciences, Inc. from March 2014 to December 2018 Concert Pharmaceuticals, Inc. from March 2014 to June 2019 and Patara Pharma, Inc. from 2015 to November 2018. Dr. Wierenga holds a B.A. from Hope College and a Ph.D. in Chemistry from Stanford University. - Wendell Wierenga，2014年9月以来，他一直担任我们董事会的成员。他是一个经验丰富的制药执行官，拥有研究、药物发现和药物开发各方面的丰富经验。从2011年6月到2014年2月，他担任Santarus公司（公共生物制药公司，于2014年1月被Salix Pharmaceuticals公司收购）的研发执行副总裁。从2007年到2011年5月，他曾担任Ambit Biosciences Corporation的执行副总裁，负责研发。从2003年到2007年，他曾担任Neurocrine Biosciences公司的负责研发的执行副总裁。从2000年到2003年，他曾担任Syrrx公司的首席执行官。从1990年到2000年，他曾担任Parke-Davis公司（Warner Lambert公司的一个部门）的全球制药科学、技术和发展的副总裁。任职Parke-Davis公司之前，他曾任职Upjohn Co。及其继任公司16年，担任多种职务，最近担任负责发现研究的执行董事。此外，他是XenoPort公司、Cytokinetics公司、Ocera Therapeutics公司、Apricus Biosciences公司、Concert Pharmaceuticals公司的董事。在之前的五年里，他此前也曾任职于Onyx Pharmaceuticals公司的董事会。他持有Hope College的学士学位，以及Stanford University的化学博士学位。
- Wendell Wierenga has served as a member of our Board of Directors since February 2011. From June 2011 to January 2014 Dr. Wierenga served as Executive Vice President, Research and Development, at Santarus, Inc., acquired by Salix Inc., which was subsequently acquired by Valeant Pharmaceuticals International, Inc. From 2006 to 2011 he served as Executive Vice President, Research and Development, at Ambit Biosciences Corporation. From 2003 to 2006 he served as Executive Vice President of Research and Development at Neurocrine Biosciences, Inc. From 2000 to 2003 Dr. Wierenga served as Chief Executive Officer of Syrrx, Inc. now part of Takeda Pharmaceutical Company. From 1990 to 2000 he was Senior Vice President of Worldwide Pharmaceutical Sciences, Technologies and Development at Parke-Davis/Warner Lambert (now Pfizer, Inc.). Prior to that, Dr. Wierenga spent 16 years at Upjohn Pharmaceuticals in research and drug discovery roles, most recently as Executive Director of Discovery Research. Dr. Wierenga has served on the Board of Directors of Crinetics Pharmaceuticals since 2014 and Dermata Therapeutics since September 2016. He also served on the Board of Directors of Onyx Pharmaceuticals, Inc. from 1996 to 2013 XenoPort, Inc. from 2001 to August 2016 Ocera Therapeutics, Inc. from December 2013 to December 2018 Anacor Pharmaceuticals, Inc. from September 2014 to July 2016 Apricus Biosciences, Inc. from March 2014 to December 2018 Concert Pharmaceuticals, Inc. from March 2014 to June 2019 and Patara Pharma, Inc. from 2015 to November 2018. Dr. Wierenga holds a B.A. from Hope College and a Ph.D. in Chemistry from Stanford University.
- Meghan FitzGerald
-
Meghan FitzGerald，自2016年3月起担任Concert Pharmaceuticals, Inc.的董事会成员。自2016年12月起，她担任L1 Health LLC（一家专注于医疗保健投资的投资基金）的管理合伙人。从2015年5月到2016年10月，她担任Cardinal Health（一家医疗保健服务和产品公司）的战略和政策执行副总裁。从2010年10月到2015年5月，她担任Cardinal Health Specialty Solutions的总裁。自2017年7月起，她担任Arix Bioscience plc（上市生物技术公司）的董事会成员。她还担任一些私人生物技术公司的董事会成员。她在纽约医学院（New York Medical College）获得公共卫生博士学位，专注于卫生政策。她还获得了哥伦比亚大学（Columbia University）的公共卫生硕士学位和费尔菲尔德大学（Fairfield University）的护理学士学位。
Meghan FitzGerald,is a global healthcare strategist, investor, academic and author. She has worked across the healthcare industry from front line patient care through the Fortune 500, and also serves as an Adjunct Professor of Health Policy at Columbia University. Ms. FitzGerald is a private equity investor where she serves as a senior advisor to several firms, including Goldman Sachs and Wellspring. Ms. FitzGerald served from December 2016 to January 2020 as the Chief Executive Officer and Managing Partner at Letter One's inaugural health vehicle, L1 Health. Prior to that, she spent twenty years working for many prominent healthcare companies, including Cardinal Heath, Medco Health Systems, Pfizer, Merck and Sanofi-Synthelabo. Currently, Ms. FitzGerald also serves on the board of directors of Tenet Healthcare and is a founder of K2HealthVentures, a life science investment fund. She previously served as a director of Thimblepoint Acquisition Corp., from February to December 2021, and Arix Bioscience plc, from 2017 to 2019. Ms. FitzGerald received a Doctor of Public Health from New York Medical College, a Master of Public Health from Columbia University and a BSN in Nursing from Fairfield University. - Meghan FitzGerald，自2016年3月起担任Concert Pharmaceuticals, Inc.的董事会成员。自2016年12月起，她担任L1 Health LLC（一家专注于医疗保健投资的投资基金）的管理合伙人。从2015年5月到2016年10月，她担任Cardinal Health（一家医疗保健服务和产品公司）的战略和政策执行副总裁。从2010年10月到2015年5月，她担任Cardinal Health Specialty Solutions的总裁。自2017年7月起，她担任Arix Bioscience plc（上市生物技术公司）的董事会成员。她还担任一些私人生物技术公司的董事会成员。她在纽约医学院（New York Medical College）获得公共卫生博士学位，专注于卫生政策。她还获得了哥伦比亚大学（Columbia University）的公共卫生硕士学位和费尔菲尔德大学（Fairfield University）的护理学士学位。
- Meghan FitzGerald,is a global healthcare strategist, investor, academic and author. She has worked across the healthcare industry from front line patient care through the Fortune 500, and also serves as an Adjunct Professor of Health Policy at Columbia University. Ms. FitzGerald is a private equity investor where she serves as a senior advisor to several firms, including Goldman Sachs and Wellspring. Ms. FitzGerald served from December 2016 to January 2020 as the Chief Executive Officer and Managing Partner at Letter One's inaugural health vehicle, L1 Health. Prior to that, she spent twenty years working for many prominent healthcare companies, including Cardinal Heath, Medco Health Systems, Pfizer, Merck and Sanofi-Synthelabo. Currently, Ms. FitzGerald also serves on the board of directors of Tenet Healthcare and is a founder of K2HealthVentures, a life science investment fund. She previously served as a director of Thimblepoint Acquisition Corp., from February to December 2021, and Arix Bioscience plc, from 2017 to 2019. Ms. FitzGerald received a Doctor of Public Health from New York Medical College, a Master of Public Health from Columbia University and a BSN in Nursing from Fairfield University.
- Wendell Wierenga
-
Wendell Wierenga于2016年9月成为董事。从2011年6月到2014年1月，Wierenga博士担任Santarus，Inc.（上市生物制药公司，2014年1月被Salix Pharmaceuticals，Inc.收购）的执行副总裁兼研究与开发。从2004年7月到2011年5月，Wierenga博士担任Ambit Biosciences Corporation and NeurocrineBiosciences，Inc.的执行副总裁、研究与开发。纳斯达克:NBIX。加入Neurocrine之前，从1999年8月到2004年6月，他担任SyrRx，Inc.的首席执行官，在那里他建立了一家早期生物技术公司，该公司于2005年被Takeda Pharmaceutical Company Limited收购。从1990年到2000年，何博士也是一名老先生。Parke Davis/Warner Lambert的研究副总裁，当时该公司被辉瑞公司收购，在此之前从1974年到1990年在Upjohn Pharmaceuticals担任多个研究职位。维伦加博士在斯坦福大学获得化学博士学位，在密歇根荷兰的希望学院获得文学学士学位。他目前是Crinetics（NASDAQ:CRNX）的董事会主席，也是Cytkinetics，Inc.（NASDAQ:CYTK）的董事会成员。最近担任Anacor Pharmaceuticals Inc.和XenoPort，Inc.的董事会成员，此前他们分别出售给辉瑞公司和Arbor Pharmaceuticals，LLC。
Wendell Wierenga,joined board of directors as Chair in October 2015. He has an extensive background serving as a public company executive and board member in the pharmaceutical and biotechnology industries. He most recently served as Executive Vice President, Research and Development, at Santarus, Inc., a specialty biopharmaceutical company, from June 2011 until its acquisition by Salix Pharmaceuticals, Inc. in 2014. Prior to Santarus, he was Executive Vice President of Research and Development at Ambit Biosciences Corporation from 2007 until 2011 and Neurocrine Biosciences, Inc. from 2003 until 2006. Additionally, Dr. Wierenga served as Chief Executive Officer of Syrrx, Inc. (now part of Takeda Pharmaceutical Company), Senior Vice President of Worldwide Pharmaceutical Sciences, Technologies and Development at Parke-Davis/Warner Lambert Company LLC (now Pfizer, Inc.), and he spent 16 years at Upjohn Pharmaceuticals in research and drug discovery roles. Dr. Wierenga serves as a member of the board of directors and compensation committee of Dermata Therapeutics, Inc. and Cytokinetics Incorporated, as well as the Chair of the science and technology committee of Cytokentics, Incorporated, both publicly traded biopharmaceutical companies. He was previously on the board of directors of Onyx Pharmaceuticals, Inc. (acquired by Amgen), Anacor Pharmaceuticals Inc. (acquired by Pfizer), XenoPort, Inc. (acquired by Arbor Pharmaceuticals), Ocera Therapeutics Inc. (acquired by Mallinckrodt), Apricus Biosciences, Inc. (acquired by Seelos), Patara Pharma LLC (acquired by Respivant), and Concert Pharmaceuticals, Inc. He holds a Ph.D. in Chemistry from Stanford University and a B.A. in Chemistry from Hope College. - Wendell Wierenga于2016年9月成为董事。从2011年6月到2014年1月，Wierenga博士担任Santarus，Inc.（上市生物制药公司，2014年1月被Salix Pharmaceuticals，Inc.收购）的执行副总裁兼研究与开发。从2004年7月到2011年5月，Wierenga博士担任Ambit Biosciences Corporation and NeurocrineBiosciences，Inc.的执行副总裁、研究与开发。纳斯达克:NBIX。加入Neurocrine之前，从1999年8月到2004年6月，他担任SyrRx，Inc.的首席执行官，在那里他建立了一家早期生物技术公司，该公司于2005年被Takeda Pharmaceutical Company Limited收购。从1990年到2000年，何博士也是一名老先生。Parke Davis/Warner Lambert的研究副总裁，当时该公司被辉瑞公司收购，在此之前从1974年到1990年在Upjohn Pharmaceuticals担任多个研究职位。维伦加博士在斯坦福大学获得化学博士学位，在密歇根荷兰的希望学院获得文学学士学位。他目前是Crinetics（NASDAQ:CRNX）的董事会主席，也是Cytkinetics，Inc.（NASDAQ:CYTK）的董事会成员。最近担任Anacor Pharmaceuticals Inc.和XenoPort，Inc.的董事会成员，此前他们分别出售给辉瑞公司和Arbor Pharmaceuticals，LLC。
- Wendell Wierenga,joined board of directors as Chair in October 2015. He has an extensive background serving as a public company executive and board member in the pharmaceutical and biotechnology industries. He most recently served as Executive Vice President, Research and Development, at Santarus, Inc., a specialty biopharmaceutical company, from June 2011 until its acquisition by Salix Pharmaceuticals, Inc. in 2014. Prior to Santarus, he was Executive Vice President of Research and Development at Ambit Biosciences Corporation from 2007 until 2011 and Neurocrine Biosciences, Inc. from 2003 until 2006. Additionally, Dr. Wierenga served as Chief Executive Officer of Syrrx, Inc. (now part of Takeda Pharmaceutical Company), Senior Vice President of Worldwide Pharmaceutical Sciences, Technologies and Development at Parke-Davis/Warner Lambert Company LLC (now Pfizer, Inc.), and he spent 16 years at Upjohn Pharmaceuticals in research and drug discovery roles. Dr. Wierenga serves as a member of the board of directors and compensation committee of Dermata Therapeutics, Inc. and Cytokinetics Incorporated, as well as the Chair of the science and technology committee of Cytokentics, Incorporated, both publicly traded biopharmaceutical companies. He was previously on the board of directors of Onyx Pharmaceuticals, Inc. (acquired by Amgen), Anacor Pharmaceuticals Inc. (acquired by Pfizer), XenoPort, Inc. (acquired by Arbor Pharmaceuticals), Ocera Therapeutics Inc. (acquired by Mallinckrodt), Apricus Biosciences, Inc. (acquired by Seelos), Patara Pharma LLC (acquired by Respivant), and Concert Pharmaceuticals, Inc. He holds a Ph.D. in Chemistry from Stanford University and a B.A. in Chemistry from Hope College.
- Peter Barton Hutt
-
Peter Barton Hutt，他是食品及药物管理局（Food and Drug Administration，FDA）的前任首席顾问，并于2005年5月成为董事。他目前担任Covington & Burling公司的华盛顿特区的律师事务所的高级顾问，专注于食品和药品法。他自1994年起在哈佛法学院（Harvard Law School）教一门食品和药品法课程，并于1998年在斯坦福法学院（ Stanford Law School）教授同一门课程。他也是《Food and Drug Law：Cases and Materials》的合著者。他是医学研究所（Institute Of Medicine） （IOM）和美国国家科学院（National Academy of Sciences）（NAS）的成员。他最近任职美国总统科学和技术顾问委员会（PCAST）的创新药物开发和评估工作组。他也曾任职各种各样的学术和顾问委员会，包括国家卫生研究所（National Institutes of Health）（NIH）的行政重组小组。此前，他曾任职the IOM的执行委员会、NIH的咨询委员会、NAS的生物医学和行为科学研究训练委员会、批准癌症和艾滋病新药的审查当前程序的全国委员会（应布什总统的要求美国国家癌症研究所创立的）。他持有耶鲁大学（Yale University）的学士学位，以及哈佛大学（Harvard University）和纽约大学（New York University）的法律学位。他目前担任BIND Therapeutics公司和Momenta Pharmaceuticals公司的董事。此前，他曾担任Ista Parmaceuticals公司的董事（从2002年到2012年），以及Celera公司的董（从2008年到2011年）。
Peter Barton Hutt has served as a member of our board of directors since March 2012. Mr. Hutt has practiced law at Covington & Burling LLP, specializing in food and drug law, since 1960 except for the period from 1971 to 1975. From 1971 to 1975 he was Chief Counsel for the U.S. Food and Drug Administration. Mr. Hutt is a member of the board of directors of Flex Pharma, Inc. (Nasdaq: FLKS), Q Therapeutics, Inc. (Nasdaq: QCEL), Concert Pharmaceuticals, Inc. (Nasdaq: CNCE), and Immunomedics, Inc. (Nasdaq: IMMU), each of which is a public biotechnology company, as well as numerous private companies. During the last five years, Mr. Hutt also served as a member of the board of directors of BIND Therapeutics, Inc. (Nasdaq: BIND), Seres Therapeutics, Inc. (Nasdaq: MCRB), Xoma Ltd. (Nasdaq: XOMA), DBV Technologies SA (Nasdaq: DBVT), Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), and Evelo Biosciences, Inc. (Nasdaq: EVLO). Mr. Hutt received a B.A. from Yale University, an LL.B. from Harvard Law School, and an LL.M. from New York University School of Law. - Peter Barton Hutt，他是食品及药物管理局（Food and Drug Administration，FDA）的前任首席顾问，并于2005年5月成为董事。他目前担任Covington & Burling公司的华盛顿特区的律师事务所的高级顾问，专注于食品和药品法。他自1994年起在哈佛法学院（Harvard Law School）教一门食品和药品法课程，并于1998年在斯坦福法学院（ Stanford Law School）教授同一门课程。他也是《Food and Drug Law：Cases and Materials》的合著者。他是医学研究所（Institute Of Medicine） （IOM）和美国国家科学院（National Academy of Sciences）（NAS）的成员。他最近任职美国总统科学和技术顾问委员会（PCAST）的创新药物开发和评估工作组。他也曾任职各种各样的学术和顾问委员会，包括国家卫生研究所（National Institutes of Health）（NIH）的行政重组小组。此前，他曾任职the IOM的执行委员会、NIH的咨询委员会、NAS的生物医学和行为科学研究训练委员会、批准癌症和艾滋病新药的审查当前程序的全国委员会（应布什总统的要求美国国家癌症研究所创立的）。他持有耶鲁大学（Yale University）的学士学位，以及哈佛大学（Harvard University）和纽约大学（New York University）的法律学位。他目前担任BIND Therapeutics公司和Momenta Pharmaceuticals公司的董事。此前，他曾担任Ista Parmaceuticals公司的董事（从2002年到2012年），以及Celera公司的董（从2008年到2011年）。
- Peter Barton Hutt has served as a member of our board of directors since March 2012. Mr. Hutt has practiced law at Covington & Burling LLP, specializing in food and drug law, since 1960 except for the period from 1971 to 1975. From 1971 to 1975 he was Chief Counsel for the U.S. Food and Drug Administration. Mr. Hutt is a member of the board of directors of Flex Pharma, Inc. (Nasdaq: FLKS), Q Therapeutics, Inc. (Nasdaq: QCEL), Concert Pharmaceuticals, Inc. (Nasdaq: CNCE), and Immunomedics, Inc. (Nasdaq: IMMU), each of which is a public biotechnology company, as well as numerous private companies. During the last five years, Mr. Hutt also served as a member of the board of directors of BIND Therapeutics, Inc. (Nasdaq: BIND), Seres Therapeutics, Inc. (Nasdaq: MCRB), Xoma Ltd. (Nasdaq: XOMA), DBV Technologies SA (Nasdaq: DBVT), Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), and Evelo Biosciences, Inc. (Nasdaq: EVLO). Mr. Hutt received a B.A. from Yale University, an LL.B. from Harvard Law School, and an LL.M. from New York University School of Law.
- Christine van Heek
-
Christine van Heek自2007年起担任董事会成员，2008年3月-2013年10月担任提名和公司治理委员会的成员，2011年5月-2013年10月成为薪酬委员会成员。她目前是BIO POINT Group（一家商务拓展咨询公司，2003年创立的）的经营合伙人。1991-2003年她在Genzyme股份有限公司（Genzyme, Inc.，一家生物技术公司）担任不同的职位，包括公司治疗部门高管和总裁。另外，她还担任Genentech股份有限公司（Genentech, Inc.）和Caremark/HHCA不同的销售和营销职位。
Christine van Heek has served as a member of our Board of Directors since April 2016. Ms. van Heek has served as an adviser and consultant to several companies in the bio-pharmaceutical industry. From 1991 to 2003 Ms. van Heek served in various roles at Genzyme, Inc., a biotechnology company, including positions as Corporate Officer and President, Therapeutics Division; General Manager, Renal Division; and Vice President, Global Marketing. In addition, she has held various sales and marketing positions at Genentech, Inc. and Caremark/HHCA. During the last five years, Ms. van Heek also served as a member of the board of directors of Affymax, Inc., a biopharmaceutical company. Ms. van Heek holds an M.B.A. from Lindenwood University in St. Louis and a B.S.N. from the University of Iowa. - Christine van Heek自2007年起担任董事会成员，2008年3月-2013年10月担任提名和公司治理委员会的成员，2011年5月-2013年10月成为薪酬委员会成员。她目前是BIO POINT Group（一家商务拓展咨询公司，2003年创立的）的经营合伙人。1991-2003年她在Genzyme股份有限公司（Genzyme, Inc.，一家生物技术公司）担任不同的职位，包括公司治疗部门高管和总裁。另外，她还担任Genentech股份有限公司（Genentech, Inc.）和Caremark/HHCA不同的销售和营销职位。
- Christine van Heek has served as a member of our Board of Directors since April 2016. Ms. van Heek has served as an adviser and consultant to several companies in the bio-pharmaceutical industry. From 1991 to 2003 Ms. van Heek served in various roles at Genzyme, Inc., a biotechnology company, including positions as Corporate Officer and President, Therapeutics Division; General Manager, Renal Division; and Vice President, Global Marketing. In addition, she has held various sales and marketing positions at Genentech, Inc. and Caremark/HHCA. During the last five years, Ms. van Heek also served as a member of the board of directors of Affymax, Inc., a biopharmaceutical company. Ms. van Heek holds an M.B.A. from Lindenwood University in St. Louis and a B.S.N. from the University of Iowa.
- Roger D. Tung
-
Roger D. Tung ，他是我们的创始人之一，曾担任我们的总裁兼首席执行官，以及我们董事会的成员（2006年4月以来）。此前，他是Vertex（一家制药公司）的创始科学家（从1989年到2005年），并于最近担任药物发现副总裁。他曾担任Merck, Sharp & Dohme Research Laboratories公司（全球医疗服务提供者）和美施贵宝药物化学研究所不同职位。他获得里德学院化学学士学位，以及麦迪逊分校药物化学博士学位。
Roger D. Tung, Ph.D. is our co-founder and has served as our President and Chief Executive Officer and as a member of our Board of Directors since April 2006. He is also a member of the board of directors of Flex Pharma, Inc., a public pharmaceutical company. Before founding Concert, Dr. Tung was a founding scientist at Vertex Pharmaceuticals Incorporated, a pharmaceutical company, where he was employed from 1989 to 2005 most recently as its Vice President of Drug Discovery. Prior to Vertex, he held various positions at Merck, Sharp & Dohme Research Laboratories, a global healthcare provider, and The Squibb Institute for Medicinal Chemistry. Dr. Tung received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry from the University of Wisconsin-Madison. - Roger D. Tung ，他是我们的创始人之一，曾担任我们的总裁兼首席执行官，以及我们董事会的成员（2006年4月以来）。此前，他是Vertex（一家制药公司）的创始科学家（从1989年到2005年），并于最近担任药物发现副总裁。他曾担任Merck, Sharp & Dohme Research Laboratories公司（全球医疗服务提供者）和美施贵宝药物化学研究所不同职位。他获得里德学院化学学士学位，以及麦迪逊分校药物化学博士学位。
- Roger D. Tung, Ph.D. is our co-founder and has served as our President and Chief Executive Officer and as a member of our Board of Directors since April 2006. He is also a member of the board of directors of Flex Pharma, Inc., a public pharmaceutical company. Before founding Concert, Dr. Tung was a founding scientist at Vertex Pharmaceuticals Incorporated, a pharmaceutical company, where he was employed from 1989 to 2005 most recently as its Vice President of Drug Discovery. Prior to Vertex, he held various positions at Merck, Sharp & Dohme Research Laboratories, a global healthcare provider, and The Squibb Institute for Medicinal Chemistry. Dr. Tung received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry from the University of Wisconsin-Madison.
- Richard H. Aldrich
-
Richard H. Aldrich是Concert Pharmaceuticals, Inc.的联合创始人，自2006年5月起担任Concert Pharmaceuticals, Inc.董事会成员和Concert Pharmaceuticals, Inc.董事会主席。Aldrich先生是联合创始人，自2010年12月以来一直是风险投资公司Longwood Fund的合伙人。Aldrich先生自2015年8月以来一直是Longwood Management LLC的雇员。Aldrich先生于2001年创立了对冲基金RA Capital Management LLC，2001年至2008年担任管理成员，2008年至2011年担任联合创始成员。Aldrich先生与他人共同创立并帮助建立了多家生物技术公司，包括Sirtris Pharmaceuticals，Inc.（2008年被葛兰素史克收购）、Alnara Pharmaceuticals，Inc.（2010年被礼来制药收购）、Verastem, Inc.、OvaScience，Inc.和FlexPharma。Aldrich先生还是Vertex Pharmaceuticals Incorporated的创始员工，曾担任高级副总裁兼首席业务官一职，并于1989年至2001年管理所有商业和经营职能。在加入Vertex公司之前，Aldrich先生曾在Biogen Inc.担任多个管理职位。Aldrich先生是OvaScience，Inc.（一家生命科学公共公司）的董事会成员，并担任OvaScience，Inc.的首席董事。Aldrich先生还担任一些私营生物技术公司的董事会成员。在过去五年中，Aldrich先生还担任PTC Therapeutics，Inc.和Verastem, Inc.的董事会成员，这两家公司都是上市生物制药公司。Aldrich先生在波士顿学院获得管理学学士学位，在达特茅斯学院的Amos Tuck学校获得工商管理硕士学位。
Richard H. Aldrich is Concert Pharmaceuticals, Inc. co-founder and has served as a member of Concert Pharmaceuticals, Inc. Board of Directors and as Chairman of Concert Pharmaceuticals, Inc. Board of Directors since May 2006. Mr. Aldrich is a co-founder and has been a Partner of Longwood Fund, a venture capital firm, since December 2010. Mr. Aldrich has been an employee of Longwood Management LLC since August 2015. Mr. Aldrich founded RA Capital Management LLC, a hedge fund, in 2001 and served as a Managing Member from 2001 to 2008 and as a Co-Founding Member from 2008 until 2011. Mr. Aldrich has co-founded and helped to build several biotechnology companies including Sirtris Pharmaceuticals, Inc., acquired by GlaxoSmithKline in 2008 Alnara Pharmaceuticals, Inc. (acquired by Eli Lilly in 2010), Verastem, Inc., OvaScience, Inc. and FlexPharma. Mr. Aldrich was also a founding employee of Vertex Pharmaceuticals Incorporated, where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen Inc. Mr. Aldrich serves on the board of directors of OvaScience, Inc., a public life sciences company, where he serves as the Lead Director. Mr. Aldrich also serves on the boards of a number of private biotechnology companies. During the last five years, Mr. Aldrich also served as a member of the board of directors of PTC Therapeutics, Inc. and Verastem, Inc., both of which are public biopharmaceutical companies. Mr. Aldrich received his B.S. in Management from Boston College and an M.B.A. from the Amos Tuck School at Dartmouth College. - Richard H. Aldrich是Concert Pharmaceuticals, Inc.的联合创始人，自2006年5月起担任Concert Pharmaceuticals, Inc.董事会成员和Concert Pharmaceuticals, Inc.董事会主席。Aldrich先生是联合创始人，自2010年12月以来一直是风险投资公司Longwood Fund的合伙人。Aldrich先生自2015年8月以来一直是Longwood Management LLC的雇员。Aldrich先生于2001年创立了对冲基金RA Capital Management LLC，2001年至2008年担任管理成员，2008年至2011年担任联合创始成员。Aldrich先生与他人共同创立并帮助建立了多家生物技术公司，包括Sirtris Pharmaceuticals，Inc.（2008年被葛兰素史克收购）、Alnara Pharmaceuticals，Inc.（2010年被礼来制药收购）、Verastem, Inc.、OvaScience，Inc.和FlexPharma。Aldrich先生还是Vertex Pharmaceuticals Incorporated的创始员工，曾担任高级副总裁兼首席业务官一职，并于1989年至2001年管理所有商业和经营职能。在加入Vertex公司之前，Aldrich先生曾在Biogen Inc.担任多个管理职位。Aldrich先生是OvaScience，Inc.（一家生命科学公共公司）的董事会成员，并担任OvaScience，Inc.的首席董事。Aldrich先生还担任一些私营生物技术公司的董事会成员。在过去五年中，Aldrich先生还担任PTC Therapeutics，Inc.和Verastem, Inc.的董事会成员，这两家公司都是上市生物制药公司。Aldrich先生在波士顿学院获得管理学学士学位，在达特茅斯学院的Amos Tuck学校获得工商管理硕士学位。
- Richard H. Aldrich is Concert Pharmaceuticals, Inc. co-founder and has served as a member of Concert Pharmaceuticals, Inc. Board of Directors and as Chairman of Concert Pharmaceuticals, Inc. Board of Directors since May 2006. Mr. Aldrich is a co-founder and has been a Partner of Longwood Fund, a venture capital firm, since December 2010. Mr. Aldrich has been an employee of Longwood Management LLC since August 2015. Mr. Aldrich founded RA Capital Management LLC, a hedge fund, in 2001 and served as a Managing Member from 2001 to 2008 and as a Co-Founding Member from 2008 until 2011. Mr. Aldrich has co-founded and helped to build several biotechnology companies including Sirtris Pharmaceuticals, Inc., acquired by GlaxoSmithKline in 2008 Alnara Pharmaceuticals, Inc. (acquired by Eli Lilly in 2010), Verastem, Inc., OvaScience, Inc. and FlexPharma. Mr. Aldrich was also a founding employee of Vertex Pharmaceuticals Incorporated, where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen Inc. Mr. Aldrich serves on the board of directors of OvaScience, Inc., a public life sciences company, where he serves as the Lead Director. Mr. Aldrich also serves on the boards of a number of private biotechnology companies. During the last five years, Mr. Aldrich also served as a member of the board of directors of PTC Therapeutics, Inc. and Verastem, Inc., both of which are public biopharmaceutical companies. Mr. Aldrich received his B.S. in Management from Boston College and an M.B.A. from the Amos Tuck School at Dartmouth College.
高管简历
中英对照 | 中文 | 英文- Lynette A. Herscha
LynetteA.Herscha自2017年6月1日起担任我们的总法律顾问兼公司秘书。此前，Herscha女士自2014年7月起担任我们的Vice President兼助理总法律顾问兼助理秘书。在加入Concert之前，Herscha女士曾在生物技术公司MomentaPharmaceuticals，Inc.和技术公司Phase Forward Incorporated担任高级法律职位。在此之前，Herscha女士曾在Fulbright&Jawksi的律师事务所工作。Herscha女士在波士顿大学（Boston University）获得法学博士学位和英语文学学士学位。
Lynette A. Herscha has served as our General Counsel and Corporate Secretary since June 1 2017. Previously, Ms. Herscha served as our Vice President and Associate General Counsel and Assistant Secretary since July 2014. Prior to joining Concert, Ms. Herscha held senior legal positions at Momenta Pharmaceuticals, Inc., a biotechnology company and Phase Forward Incorporated, a technology company. Prior to that, Ms. Herscha worked in the law offices of Fulbright & Jaworksi. Ms. Herscha earned her Juris Doctor and B.A. in English from Boston University.- LynetteA.Herscha自2017年6月1日起担任我们的总法律顾问兼公司秘书。此前，Herscha女士自2014年7月起担任我们的Vice President兼助理总法律顾问兼助理秘书。在加入Concert之前，Herscha女士曾在生物技术公司MomentaPharmaceuticals，Inc.和技术公司Phase Forward Incorporated担任高级法律职位。在此之前，Herscha女士曾在Fulbright&Jawksi的律师事务所工作。Herscha女士在波士顿大学（Boston University）获得法学博士学位和英语文学学士学位。
- Lynette A. Herscha has served as our General Counsel and Corporate Secretary since June 1 2017. Previously, Ms. Herscha served as our Vice President and Associate General Counsel and Assistant Secretary since July 2014. Prior to joining Concert, Ms. Herscha held senior legal positions at Momenta Pharmaceuticals, Inc., a biotechnology company and Phase Forward Incorporated, a technology company. Prior to that, Ms. Herscha worked in the law offices of Fulbright & Jaworksi. Ms. Herscha earned her Juris Doctor and B.A. in English from Boston University.
- James V. Cassella
James V. Cassella，2012年7月以来，担任执行副总裁、首席研发科学官；从2004年6月至2012年7月，担任研究和开发高级副总裁。从1989年4月到2004年4月，担任Neurogen公司的不同管理职位，这是一个上市的生物技术公司，从2003年1月至2004年6月，他担任高级副总裁、临床研究和发展负责人。加入Neurogen之前，他担任欧柏林大学神经科学副教授。他获得了达特茅斯学院生理心理学博士学位获得了完成了耶鲁大学医学院的精神病学博士后奖学金和纽黑文大学的心理学学士学位。
James V. Cassella has served as our Senior Vice President and Chief Development Officer since February 2015. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from June 2004 to July 2012. From April 1989 to April 2004 Dr. Cassella held various management positions at Neurogen Corporation, a publicly traded biotechnology company. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received a Ph.D. in physiological psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in psychology from the University of New Haven.- James V. Cassella，2012年7月以来，担任执行副总裁、首席研发科学官；从2004年6月至2012年7月，担任研究和开发高级副总裁。从1989年4月到2004年4月，担任Neurogen公司的不同管理职位，这是一个上市的生物技术公司，从2003年1月至2004年6月，他担任高级副总裁、临床研究和发展负责人。加入Neurogen之前，他担任欧柏林大学神经科学副教授。他获得了达特茅斯学院生理心理学博士学位获得了完成了耶鲁大学医学院的精神病学博士后奖学金和纽黑文大学的心理学学士学位。
- James V. Cassella has served as our Senior Vice President and Chief Development Officer since February 2015. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from June 2004 to July 2012. From April 1989 to April 2004 Dr. Cassella held various management positions at Neurogen Corporation, a publicly traded biotechnology company. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received a Ph.D. in physiological psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in psychology from the University of New Haven.
- Roger D. Tung
Roger D. Tung ，他是我们的创始人之一，曾担任我们的总裁兼首席执行官，以及我们董事会的成员（2006年4月以来）。此前，他是Vertex（一家制药公司）的创始科学家（从1989年到2005年），并于最近担任药物发现副总裁。他曾担任Merck, Sharp & Dohme Research Laboratories公司（全球医疗服务提供者）和美施贵宝药物化学研究所不同职位。他获得里德学院化学学士学位，以及麦迪逊分校药物化学博士学位。
Roger D. Tung, Ph.D. is our co-founder and has served as our President and Chief Executive Officer and as a member of our Board of Directors since April 2006. He is also a member of the board of directors of Flex Pharma, Inc., a public pharmaceutical company. Before founding Concert, Dr. Tung was a founding scientist at Vertex Pharmaceuticals Incorporated, a pharmaceutical company, where he was employed from 1989 to 2005 most recently as its Vice President of Drug Discovery. Prior to Vertex, he held various positions at Merck, Sharp & Dohme Research Laboratories, a global healthcare provider, and The Squibb Institute for Medicinal Chemistry. Dr. Tung received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry from the University of Wisconsin-Madison.- Roger D. Tung ，他是我们的创始人之一，曾担任我们的总裁兼首席执行官，以及我们董事会的成员（2006年4月以来）。此前，他是Vertex（一家制药公司）的创始科学家（从1989年到2005年），并于最近担任药物发现副总裁。他曾担任Merck, Sharp & Dohme Research Laboratories公司（全球医疗服务提供者）和美施贵宝药物化学研究所不同职位。他获得里德学院化学学士学位，以及麦迪逊分校药物化学博士学位。
- Roger D. Tung, Ph.D. is our co-founder and has served as our President and Chief Executive Officer and as a member of our Board of Directors since April 2006. He is also a member of the board of directors of Flex Pharma, Inc., a public pharmaceutical company. Before founding Concert, Dr. Tung was a founding scientist at Vertex Pharmaceuticals Incorporated, a pharmaceutical company, where he was employed from 1989 to 2005 most recently as its Vice President of Drug Discovery. Prior to Vertex, he held various positions at Merck, Sharp & Dohme Research Laboratories, a global healthcare provider, and The Squibb Institute for Medicinal Chemistry. Dr. Tung received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry from the University of Wisconsin-Madison.
- Nancy Stuart
Nancy Stuart从2007年10月到2023年3月担任Concert Pharmaceuticals Inc.（生物制药公司，随后被Sun Pharmaceutical Industries Limited收购）的首席运营官，从2006年7月到2007年10月担任公司战略和运营高级副总裁。在加入Concert之前，她曾在Amgen Inc.（生物制药公司）、Kinetix Pharmaceuticals, Inc.（制药公司，随后被Amgen收购）、Vertex（制药公司）和Genzyme Corporation（生物技术公司，随后被Sanofi S.A.收购）担任各种业务运营和业务发展职位。她还担任the Greater Boston YMCA的董事会成员。她持有Michigan大学的理学士学位和the Simmons Graduate School of Management的工商管理硕士学位。
Nancy Stuart,served as the Chief Operating Officer of Concert Pharmaceuticals Inc., a biopharmaceutical company subsequently acquired by Sun Pharmaceutical Industries Limited, from October 2007 to March 2023, and Senior Vice President, Corporate Strategy and Operations from July 2006 to October 2007. Prior to joining Concert, Ms. Stuart held various business operations and business development positions at Amgen Inc., a biopharmaceutical company, Kinetix Pharmaceuticals, Inc., a pharmaceutical company subsequently acquired by Amgen, Vertex, a pharmaceutical company and Genzyme Corporation, a biotechnology company subsequently acquired by Sanofi S.A. She also serves on the board of directors of The Greater Boston YMCA. Ms. Stuart holds a B.S. from the University of Michigan and an M.B.A. from the Simmons Graduate School of Management.- Nancy Stuart从2007年10月到2023年3月担任Concert Pharmaceuticals Inc.（生物制药公司，随后被Sun Pharmaceutical Industries Limited收购）的首席运营官，从2006年7月到2007年10月担任公司战略和运营高级副总裁。在加入Concert之前，她曾在Amgen Inc.（生物制药公司）、Kinetix Pharmaceuticals, Inc.（制药公司，随后被Amgen收购）、Vertex（制药公司）和Genzyme Corporation（生物技术公司，随后被Sanofi S.A.收购）担任各种业务运营和业务发展职位。她还担任the Greater Boston YMCA的董事会成员。她持有Michigan大学的理学士学位和the Simmons Graduate School of Management的工商管理硕士学位。
- Nancy Stuart,served as the Chief Operating Officer of Concert Pharmaceuticals Inc., a biopharmaceutical company subsequently acquired by Sun Pharmaceutical Industries Limited, from October 2007 to March 2023, and Senior Vice President, Corporate Strategy and Operations from July 2006 to October 2007. Prior to joining Concert, Ms. Stuart held various business operations and business development positions at Amgen Inc., a biopharmaceutical company, Kinetix Pharmaceuticals, Inc., a pharmaceutical company subsequently acquired by Amgen, Vertex, a pharmaceutical company and Genzyme Corporation, a biotechnology company subsequently acquired by Sanofi S.A. She also serves on the board of directors of The Greater Boston YMCA. Ms. Stuart holds a B.S. from the University of Michigan and an M.B.A. from the Simmons Graduate School of Management.
- Marc Becker
Marc Becker自2018年1月起担任我们的首席财务官兼首席财务官。在加入Concert之前，贝克先生于2016年2月至2017年9月担任CRISPR Therapeutics（一家公开上市的生物技术公司）的首席财务官。2012年1月至2016年2月，Becker先生是生物技术公司Revo Biologics的首席财务官。在加入Revo Biologics之前，Becker先生从2001年8月到2011年10月在Genzyme担任越来越重要的职务，最终担任财务Vice President。Becker先生在巴布森学院（Babson College）获得工商管理硕士学位，在马萨诸塞大学（University of Massachusetts）获得工商管理学士学位，并获得注册会计师执照。
Marc Becker has served as our Chief Financial Officer and principal financial officer since January 2018. Prior to joining Concert, Mr. Becker served as the Chief Financial Officer of CRISPR Therapeutics, a publicly traded biotechnology company, from February 2016 to September 2017. From January 2012 to February 2016 Mr. Becker was the Chief Financial Officer of rEVO Biologics, a biotechnology company. Prior to rEVO Biologics, Mr. Becker held increasing roles of responsibility at Genzyme from August 2001 to October 2011 culminating in Vice President, Finance. Mr. Becker received an M.B.A. from Babson College and a B.S. in Business Administration from the University of Massachusetts and was licensed as a certified public accountant.- Marc Becker自2018年1月起担任我们的首席财务官兼首席财务官。在加入Concert之前，贝克先生于2016年2月至2017年9月担任CRISPR Therapeutics（一家公开上市的生物技术公司）的首席财务官。2012年1月至2016年2月，Becker先生是生物技术公司Revo Biologics的首席财务官。在加入Revo Biologics之前，Becker先生从2001年8月到2011年10月在Genzyme担任越来越重要的职务，最终担任财务Vice President。Becker先生在巴布森学院（Babson College）获得工商管理硕士学位，在马萨诸塞大学（University of Massachusetts）获得工商管理学士学位，并获得注册会计师执照。
- Marc Becker has served as our Chief Financial Officer and principal financial officer since January 2018. Prior to joining Concert, Mr. Becker served as the Chief Financial Officer of CRISPR Therapeutics, a publicly traded biotechnology company, from February 2016 to September 2017. From January 2012 to February 2016 Mr. Becker was the Chief Financial Officer of rEVO Biologics, a biotechnology company. Prior to rEVO Biologics, Mr. Becker held increasing roles of responsibility at Genzyme from August 2001 to October 2011 culminating in Vice President, Finance. Mr. Becker received an M.B.A. from Babson College and a B.S. in Business Administration from the University of Massachusetts and was licensed as a certified public accountant.